Capital keeps pricing structure, not just spread
$1.11 billion. Fifteen transactions. Nine sectors. A warehouse refinance for an aviation lessor, a non-dilutive facility for a late-stage gene therapy company, an asset-based line for a German department store, a cross-border facility for a Mexican fintech, and a steady tail of healthcare and speciality deals that most roundups ignore.
The headline is not the largest cheque. It is how many different categories of lenders competed for the same thing last week: well-structured, well-collateralised books they can value, monitor and price with confidence. Spread still matters. Structure is what got these deals done.
Here are the transactions that matter, and why.
ATLAS SP to Aquila Air Capital, $400MM aviation warehouse
ATLAS SP Partners closed a $400 million refinancing and upsizing of the warehouse facility for Aquila Air Capital, the Ireland-based aviation lessor backed by funds managed by Wafra. ATLAS, the warehouse finance and securitised products business majority owned by Apollo funds, acted as structuring agent and lead lender. Aquila runs a diversified portfolio of more than 130 aircraft and engine assets across 25 lease customers.
Why it matters:
Aviation and equipment finance keeps upsizing while other corners of the market wait for rate clarity. A warehouse facility is designed to scale with the collateral, not the cycle. When a lessor grows its engine book, the facility grows with it, provided the assets, appraisals and cash flows are tracked with precision. This is asset-based finance in its purest form, capital sized to the value and performance of hard collateral.
Key risks:
Residual value risk on ageing engines and aircraft, lessee concentration and counterparty credit, and the discipline of continuous appraisal against a moving asset base. A warehouse is only as strong as the borrowing base behind it.
Opportunity:
For structured lenders, aviation remains a category where deep asset expertise and precise monitoring earn a premium. The lessors that can present a clean, well-tracked collateral pool get flexible structures and competitive pricing. The lenders that can monitor at asset level get to underwrite growth rather than fear it.
Hercules Capital to 4D Molecular Therapeutics, $200MM venture debt
4D Molecular Therapeutics, a late-stage gene therapy company, entered a senior secured facility of up to $200 million with Hercules Capital. The company drew $20 million at closing, with further tranches unlocked by milestones and lender approval, and a maturity in 2031. Leerink Partners advised on the structure.
Why it matters:
Non-dilutive venture debt has moved from last resort to core balance-sheet strategy for late-stage life sciences. 4DMT already holds a strong cash position. It took the facility to diversify its capital structure and preserve equity while it advances its pipeline. Milestone-linked tranches mean the capital arrives as the science de-risks, aligning funding with clinical progress.
Key risks:
Clinical and regulatory binary outcomes, cash burn against milestone timelines, and minimum liquidity and market-capitalisation covenants that tie funding availability to performance. The structure protects the lender, but it needs constant covenant and trigger tracking.
Opportunity:
Venture and growth debt lenders are underwriting an expanding pipeline of biotech and medtech names that want capital without dilution. The winners are the platforms that can monitor covenants, milestones and cash runway continuously, and act early when a trigger is approaching rather than after it breaches.
Gordon Brothers to GALERIA, €160M cross-border retail ABL
Gordon Brothers provided the German department store group GALERIA with an asset-based facility of up to €160 million, roughly $182 million, to fund its store footprint optimisation and business realignment. The structure is built around GALERIA’s inventory and real estate assets.
Why it matters:
Retail asset-based lending is alive precisely where the collateral can be valued and monitored. A department store in transformation is exactly the kind of complex, asset-heavy borrower that specialist ABL firms understand and that many bank syndicates will not underwrite. Advance rates move with appraised inventory and real estate value, so the facility must be re-based continuously as the business reshapes itself.
Key risks:
Retail turnaround execution, inventory obsolescence and seasonality, real estate valuation in a soft market, and the operational challenge of tracking a borrowing base that changes as stores close and assortments shift.
Opportunity:
Cross-border retail ABL rewards lenders who can appraise, advance against and monitor mixed collateral pools in real time. The transformation stories that scare generalist capital are the ones speciality lenders can price, because they can see and value the assets underneath.
Encina Private Credit to healthcare services, $90MM
Encina Private Credit acted as administrative and collateral agent on a $90 million senior secured facility for an undisclosed healthcare services business, structured as a $10 million revolver and an $80 million term loan.
Why it matters:
Healthcare is one of the most consistent categories in US speciality credit, and it rarely makes headlines. A revolver plus term loan structure funds both working capital and growth in a single facility, with the agent role placing Encina at the centre of collateral control and reporting.
Key risks:
Reimbursement and regulatory exposure, receivables quality and payer concentration, and covenant headroom across a blended revolver and term structure.
Opportunity:
Healthcare services financing rewards lenders who can normalise messy operating and collateral data into a clean, monitorable borrowing base. The agent that controls the data controls the relationship.
Victory Park Capital to Digitt, $50MM cross-border lender finance
Victory Park Capital provided a $50 million asset-backed facility to Digitt, a Guadalajara-based fintech that refinances high-interest credit card debt for prime borrowers in Mexico into fixed-rate installment loans. VPC, headquartered in Chicago and a majority-owned affiliate of Janus Henderson, specialises in private credit and asset-backed finance.
Why it matters:
Lender finance is crossing borders. Every dollar advanced to a speciality originator like Digitt enables multiples of downstream lending. The facility is asset-backed, secured by the underlying loan book, so performance depends on the quality of Digitt’s underwriting and servicing, not just its growth ambitions.
Key risks:
Double leverage and exposure to both the originator and its end-borrower pool, currency and macro risk in an emerging market, and transparency into a consumer book that sits one layer removed from the lender.
Opportunity:
Private credit is funding fintech origination well beyond US borders. The edge belongs to lenders who can ingest and monitor an originator’s loan tape at end-borrower level, tracking concentration, delinquency and performance continuously rather than trusting a monthly summary.
Mountain Ridge Capital to a college bookstore operator, $55MM
Mountain Ridge Capital provided a $55 million senior secured credit facility to an undisclosed college bookstore operator.
Why it matters:
Retail ABL for a seasonal, inventory-heavy operator is classic speciality territory. Bookstore economics swing hard around academic calendars, which makes a well-sized, well-monitored borrowing base essential rather than optional.
Key risks:
Seasonality and inventory turn, structural pressure on physical retail, and advance-rate discipline against collateral that moves quickly.
Opportunity:
Lenders who can track inventory eligibility and seasonality in real time can lend confidently into cash-flow patterns that scare generalist capital.
Stifel Venture Banking to Shoulder Innovations, $50MM medtech venture debt
Stifel Venture Banking provided Shoulder Innovations, a medical device company, with a $15 million term loan, a $30 million undrawn line of credit and a $5 million accordion, $50 million of total capacity.
Why it matters:
Medtech joins biotech in the non-dilutive venture debt story. A staged structure, drawn term loan plus undrawn capacity plus accordion, lets a growth-stage device company fund commercialisation without giving up equity, and gives the lender optionality tied to performance.
Key risks:
Commercialisation execution, regulatory and reimbursement pathways for devices, and cash runway against undrawn capacity that depends on milestones.
Opportunity:
Venture lenders who can monitor drawdown conditions, covenants and cash runway continuously can support the full commercial journey rather than a single tranche.
The healthcare and skilled nursing tail
Three more healthcare deals compounded quietly last week. Cambridge Realty Capital arranged a $21.5 million bridge-to-HUD first mortgage for a skilled nursing facility, financing the gap to permanent government-backed funding. SixCap Healthcare Finance closed two skilled nursing facilities in the same week, a $2 million asset-based facility and a $2 million revolving line of credit.
Why it matters:
Skilled nursing bridge and asset-based lending is among the most under-discussed durable categories in US speciality credit. It is granular, collateral-rich and relentless in volume, week after week.
Key risks:
Reimbursement and regulatory exposure, facility-level operating performance, and the transition risk inherent in bridge-to-HUD structures.
Opportunity:
Consistency compounds. Lenders and asset managers who can onboard and monitor many small, collateral-backed healthcare facilities at scale build a durable, diversified book that most of the market overlooks.
The rest of the spectrum
Nine sectors, one week. Alongside the deals above, Rosenthal Capital Group and FGI Finance backed an undisclosed luxury womenswear brand with a $25 million asset-based facility and a $4 million term loan. Wells Fargo provided a $25 million revolving credit facility to consumer health-tech company Owlet. Republic Business Credit funded a $2 million e-commerce ABL facility for an Amazon third-party seller. Franklin Capital arranged a $3 million factoring facility for a global consumer brand and logistics company. Southstar Capital provided an $0.8 million accounts receivable line, in this table an $0.4 million facility, for a commercial printing and embroidery business.
Different lenders, different scales, different sectors. The same operational discipline underneath every one.
Takeaways
- Non-dilutive venture debt is now default infrastructure for late-stage biotech and medtech, not a fallback. Hercules and Stifel both funded innovation last week without touching equity.
- Structured asset finance keeps upsizing. ATLAS SP’s warehouse refinance for Aquila shows capital chasing quality collateral through the cycle rather than waiting for it.
- Lender finance is crossing borders. Victory Park’s facility for Mexico’s Digitt shows private credit funding speciality origination well beyond the US.
- Healthcare asset-based finance stays the quiet compounder. Encina, Cambridge Realty and SixCap prove the category delivers durable, collateral-rich volume every single week.
- And across all of it, the market is pricing structure, not just spread. The lenders winning these deals are the ones who can see, value and monitor the collateral underneath.
How Cardo AI helps asset managers and lenders
From a $400 million aviation warehouse to an $800,000 working capital line, the operational requirement is identical. Collect, normalise, monitor and report on loan and collateral data, continuously, at scale. That is the operating system we have built.
We ingest loan tapes across any source or format, so a rail lessor, a skilled nursing portfolio and a Mexican consumer loan book all live in one place. We compute borrowing base, eligibility and waterfall automatically, so advance rates re-base as the collateral moves. We monitor concentration, covenants and triggers in real time, so a breach is a signal you act on early, not a surprise you find late. We run portfolio analytics and stress testing across asset classes, and we produce institutional-grade investor reporting on the same clean data.
The result is simple. Lenders underwrite growth instead of fearing it, and asset managers report with confidence instead of chasing spreadsheets. Whatever the asset class, the discipline is the same, and so is the infrastructure.
Sources
ABL Advisor deal tables (June 29–July 3, 2026); company press releases via Business Wire, GlobeNewswire, PR Newswire and Bloomberg; ABF Journal; and issuer investor relations pages.
If you’re scaling an asset-based or private credit book, we should talk.